Added to YB: 2026-08-07
Pitch date: 2026-08-05
PRQR [neutral]
ProQR Therapeutics N.V.
-4.04%
current return
Author Info
No bio for this author
Company Info
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
Market Cap
$240.8M
Pitch Price
$1.98
Price Target
3.10 (+57%)
Dividend
N/A
EV/EBITDA
-4.03
P/E
-3.95
EV/Sales
12.86
Sector
Biotechnology
Category
value
PRQR ADAR-EON
PRQR (overview): Microcap ($243M MC, <$200M EV) w/ stale data profile masking Axiomer ADAR RNA-editing platform. 3 de-risking catalysts (2026 clean safety/PK, human proof-of-mechanism + Lilly deal up to 10 targets, Ipsen competitor failure) yet stock stuck ~$1.75 vs $3.10 52wk high, dragged by June dilution. Preclinical beats AstraZeneca knockdown (82% vs 36% steatosis) & ERT. WVE peer ~$1.38B; comps trade higher for narrower bets. Risk: preclinical-to-clinical translation.
Read full article (7 min)